Cordyceps Sunshine Biotech Holdings Past Earnings Performance
Past criteria checks 3/6
Cordyceps Sunshine Biotech Holdings has been growing earnings at an average annual rate of 14.9%, while the Personal Products industry saw earnings growing at 11.7% annually. Revenues have been growing at an average rate of 39.8% per year.
Key information
14.9%
Earnings growth rate
n/a
EPS growth rate
| Personal Products Industry Growth | 20.9% |
| Revenue growth rate | 39.8% |
| Return on equity | n/a |
| Net Margin | 27.4% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
No updates
Recent updates
No updates
Revenue & Expenses Breakdown
How Cordyceps Sunshine Biotech Holdings makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 1 | 0 | 1 | 0 |
| 30 Sep 23 | 1 | 0 | 0 | 0 |
| 31 Dec 22 | 0 | 0 | 0 | 0 |
| 30 Sep 22 | 0 | -1 | 0 | 0 |
| 30 Jun 22 | 1 | -1 | 0 | 0 |
| 31 Mar 22 | 1 | -1 | 0 | 0 |
| 31 Dec 21 | 0 | 0 | 0 | 0 |
| 31 Dec 20 | 0 | 0 | 0 | 0 |
Quality Earnings: RAJA.F has high quality earnings.
Growing Profit Margin: RAJA.F became profitable in the past.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: RAJA.F has become profitable over the past 5 years.
Accelerating Growth: RAJA.F has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: RAJA.F has become profitable in the last year, making it difficult to compare its past year earnings growth to the Personal Products industry (14.8%).
Return on Equity
High ROE: RAJA.F's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.